FLT3 and acute myeloid leukemia: AML patients receive potentially cardiotoxic drugs such as anthracyclines [3,4,5,6,7] and drugs with corrected QT interval (QTc) prolongations, such as FLT3 inhibitors [8,9,10,11] and azoles, among others [12,13].